Among stroke survivors, the risk of developing dementia after stroke is significantly high, highlighting the need for targeted prevention strategies.

In a trial, sotagliflozin use in patients with diabetes and chronic kidney disease (CKD) was associated with lower risk of ischemic cardiovascular outcomes.

A clot-busting drug recently approved to treat acute ischemic strokes (AIS) that can be delivered quickly works as well as a ...

Dr. Ayo presents his final in the series of Heart and Stroke month preventative care tips in Part 6 during Heart and Stroke awareness ...

A boxed warning for testosterone on major adverse cardiovascular events is out and a new blood pressure warning is in, the ...

For patients with type 2 diabetes, chronic kidney disease, and additional cardiovascular risk factors, the dual sodium ...

Strong results to date of Vafseo U.S. launch; expect Vafseo Q1 2025 net product revenues of approximately $10-$11 millionCash resources and cash ...

The FDA has approved TNKase, a new, fast-acting stroke treatment that dissolves blood clots more efficiently, marking a significant advancement in stroke therapy and clot-busting technology.

Contemporary estrogen-progestin contraceptives are associated with an increased risk for ischemic stroke and myocardial infarction.

In recent years, the rate of cardiovascular mortality following high-risk myocardial infarction has significantly declined.

Genentech has had the lone medicine on the market for the acute treatment of stroke. | Over nearly the last three decades, ...